Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 2/20 | 0.37 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.37 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.37 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.37 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.37 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.37 |
| ▸ | GRIK3 | Q13003 | 1/20 | 0.37 |
| ▸ | KIF11 | P52732 | 7/20 | 0.37 |
| ▸ | ALPI | P09923 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | XIAP | P98170 | 1/20 | 0.35 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.35 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.34 |
| ▸ | NOS3 | P29474 | 1/20 | 0.34 |
| ▸ | NOS1 | P29475 | 1/20 | 0.34 |
| ▸ | NOS2 | P35228 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5319507 | 0.86 | NOS3 (0.44) | GRIA2ALPIPKMPTGS1XIAP | |
| SCHEMBL5326842 | 0.78 | GRIK1 (0.37) | GRIK1GRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL12319673 | 0.74 | TAAR1 (0.40) | — | |
| SCHEMBL5324384 | 0.72 | GRIK1 (0.49) | GRIK1GRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL5326906 | 0.72 | GRIK1 (0.49) | GRIK1GRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL11754720 | 0.70 | KDM4C (0.46) | KIF11PKM | |
| SCHEMBL12319675 | 0.70 | PNMT (0.42) | — | |
| SCHEMBL1520030 | 0.70 | KDM4E (0.56) | GRIK1GRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL7185336 | 0.69 | SLC6A2 (0.36) | — | |
| SCHEMBL31369908 | 0.69 | KYNU (0.49) | GRIK1GRIA1GRIA2GRIA3GRIA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070258899-A1 | Diagnostic and therapeutic agents | KARYON-CTT LTD (FI) | 2007-11-08 | — | — | US | disclosed |
| WO-2007113385-A1 | DIAGNOSTIC AND THERAPEUTIC AGENTS | KARYON-CTT LTD (FI) | 2007-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070258899-A1 | Diagnostic and therapeutic agents | YBX1, MLX, TPX2 | GRIK1 4162/4885GRIA1 3993/4885GRIA2 4396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.